HealthQuill Zepbound
Tirzepatide is an approved GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) treatment for chronic weight management, commercialised as Zepbound in the US and Mounjaro in some global markets outside the US.
Drugs Health Pharma

Eli Lilly’s Zepbound resolves sleep apnea in more than half of trial patients 

Tirzepatide, an obesity drug of  Eli Lilly and Company, has helped resolve moderate-to-severe obstructive sleep apnea in 52.% of adult patients in two.

Read More
Novo Nordisk, a Danish drugmaker, announced its weight-loss medicine, Wegovy, will be available in the UK in a “controlled and limited” manner.
Drugs Health Pharma

Eli Lilly’s LillyDirect offers direct access to obesity medication

HQ team January 6, 2024: Eli Lilly, the pharmaceutical company will now be selling its weightless drug directly to the consumer via its.

Read More
Eli Lilly’s weight-loss injection Zepbound, taken along as a supplement with diet and exercise, got the USFDA and UK regulator’s nod after clinical trials proved adults lost 48 pounds on average during treatment.
Drugs Medical Pharma

Eli Lilly’s Zepbound outperforms Novo’s Wegovy in weight loss study

HQ team November 28, 2023: A recent comparative analysis of Eli Lilly and Novo Nordisk’s weight loss drugs on diabetes patients showed Eli.

Read More
X